People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allovir, Inc. | — | Biotechnology | Series D+ | $151.3M | $5.0B | 2018 |
| iTeos Therapeutics, Inc. | — | Pharma | Series D+ | $125.4M | $4.4B | 2020 |
| NextPoint Therapeutics, Inc. | — | Biotechnology | Series C | $122.5M | $443.6M | 2022 |
| Reunion Neuroscience, Inc. | — | Pharmaceuticals | Series D+ | $119.8M | $1.5B | 2024 |
| Elixir Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.5M | 2009 |
| Mitokyne, Inc. | — | Pharmaceuticals | Series A | $5.2M | $161.7M | 2013 |
| Cerimon Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.7M | $8.9M | 2009 |
Ansbert Gadicke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ansbert Gadicke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Detlev Biniszkiewicz | 2 | 4 |
| David Hallal | 2 | 2 |
| John Wilson | 1 | 11 |
| Briggs Morrison | 1 | 8 |
| Alon Lazarus | 1 | 7 |
| R. Jacob Vogelstein | 1 | 6 |
| Robert Alexander | 1 | 6 |
| Michael Ehlers | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| David Cordo | 1 | 6 |
| Robert Adelman | 1 | 5 |
| Paulina Hill | 1 | 5 |
| Edward Smith | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Kazumi Shiosaki | 1 | 4 |
| James H. Welch | 1 | 3 |
| Nathan Bryson | 1 | 3 |
| Vaughn Kailian | 1 | 3 |
| Richard Aldrich | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.